Thank you to the American Cancer Society for highlighting our lab, this means a great deal.
Please join the Making Strides Against Breast Cancer Fundraiser October 17, 2026
www.facebook.com/groups/makin...
22.01.2026 19:23 — 👍 1 🔁 0 💬 0 📌 0
The New England Journal of Medicine
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025
Visual representations of the patients in the trial and the treatments they were assigned.
Read the full Research Summary at NEJM.org.
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg
26.12.2025 14:23 — 👍 8 🔁 3 💬 0 📌 0
Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor.
Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.
Proposed Action
We propose the following approaches to make early ToDA of ICI feasible in daily routine practice:
•
ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment;
•
AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center);
•
ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended;
•
ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs;
•
ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.
🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding.
Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!
21.12.2025 17:39 — 👍 3 🔁 1 💬 1 📌 0
Metabolites as agents and targets for cancer immunotherapy
Nature Reviews Drug Discovery - Tumour cells undergo profound changes in their metabolism, but targeting these metabolic pathways requires understanding of the impact on immune cells as well as...
For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms
rdcu.be/eLS8A
www.nature.com/articles/s41...
20.10.2025 14:47 — 👍 3 🔁 4 💬 0 📌 0
🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀
Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities.
Sign up. Stay informed. Join the movement: www.nycures.org/
04.09.2025 16:32 — 👍 47 🔁 55 💬 4 📌 6
here is our detailed schematic!
22.08.2025 19:43 — 👍 4 🔁 0 💬 1 📌 0
Isolation and Ex Vivo Testing of CD8+ T-Cell Division and Activation Using Mouse Splenocytes
This protocol describes an ex vivo co-culture method to assess CD8+ T-cell activation, proliferation, and cytotoxic potential using bulk splenocytes isolated from immunocompetent mice. Mouse splenocyt...
Happy to share our @bio-protocol.bsky.social describing an ex vivo method to measure CD8+ T-cell function. This was used in our recent papers in @emboreports.org (2025) and Molecular Cancer Therapeutics (2024).
Thanks to Melissa Dolan for leading this effort - Congratulations to the whole team!
22.08.2025 19:43 — 👍 6 🔁 0 💬 1 📌 1
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
19.08.2025 20:30 — 👍 12 🔁 5 💬 1 📌 0
It’s out!!!!! We hope our review on aging, immunity, and cancer is helpful.
Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social
So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
14.08.2025 13:17 — 👍 29 🔁 11 💬 0 📌 2
The Downsides of Therapies - And What to Do About Them
Two common forms of cancer therapy can (in some cases) lead to further metastatic cancer themselves. What to do to fix that:
22.07.2025 20:08 — 👍 23 🔁 8 💬 1 📌 0
03.02.2026 00:16 — 👍 0 🔁 0 💬 0 📌 0
